SK pharmteco subsidiary Yposkesi launches AAVelocity, a plug-and-play AAV platform

Published: 7-Nov-2023

Designed to shorten turnaround on manufacturing AAVs, this new platform offers CGT developers more flexibility when producing viral vectors for clinical and commercial use

Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for cell and gene therapies (CGTs), has launched AAVelocity, a plug-and-play adeno-associated virus (AAV) platform.

AAVelocity is designed to bring cost and time-efficiencies to drug developers in the production of AAV gene delivery systems used to transport a gene therapy into tissue to prevent, treat or cure inherited disorders and rare diseases.

The AAVelocity plug-and-play platform can provide a 12-month turnaround on drug developer projects, lowering industry average standard bioprocessing timeframes by at least 6 months and helping clients save on associated costs.

Also new is AAVelocity’s inherent flexibility. This enables bioproduction teams to easily adapt to client requirements, such as achieving different purity levels within strict time constraints.

It includes delivering AAVs containing the optimized amount of genetic material.  AAVelocity's agility also avoids intermediary steps or the addition of others, while ensuring total integrity and purity of the genetic material.

The improved efficacy of AAVelocity will bring greater benefits to drug developers and their pipelines, according to SK pharmteco.

Using single-use bioreactors, the AAV platform is scalable to meet any client need: 10 L > 50 L > 200 L > 2 x 200 L > 1000 L.
“SK pharmteco, through Yposkesi, is pleased to launch a second platform for viral vector manufacturing with enhanced plug-and-play capabilities."

"Leveraging Yposkesi’s many years of expertise, SK pharmteco is able to offer a genuine cost and time-effective solution for AAV manufacturing to stay in step with the increasing development and approvals of CGT treatments we are witnessing today, which are set to evolve in the near future,” said Alain Lamproye, Yposkesi Division Head.

“AAVelocity will bring tangible benefits to the CGT market: high yields, scalability, robustness, consistency and flexibility like no other."

"Clients can also benefit considerably from Yposkesi’s strong track record in AAV manufacturing and its experience of participating in filing six IND[1]/IMPDs of AAV-based products since 2017.”

The strengthening of AAV manufacturing at its subsidiary aligns with SK pharmteco’s positioning to meet the growing demand.

You may also like